Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users

RationaleChronic recreational ecstasy (MDMA) use has often been reported to be associated with psychopathology, memory impairments and serotonergic alterations. However, the findings have not been consistent.ObjectivesTo attempt to replicate these findings, to investigate whether such alterations would be reversible and whether they could be predicted by parameters of previous drug use.MethodsIn a cross-sectional design, 30 current and 31 ex-ecstasy users with ecstasy abstinence of at least 5 months, and 29 polydrug and 30 drug-naive controls were compared on measures of psychopathology, cognitive performance and serotonin transporter availability.ResultsThe groups did not differ significantly in age, gender distribution, education level and premorbid intelligence. The ecstasy groups did not differ significantly from polydrug controls on most of the relevant parameters of concomitant illegal drug use. Reported drug use was confirmed by hair and urine analyses. All three groups of drug users exhibited significantly elevated psychopathology compared with drug-naive controls. Only ex-ecstasy users were significantly impaired on verbal recall. Current ecstasy users showed significantly reduced distribution volume ratios of serotonin transporter availability in the mesencephalon and caudate nucleus. Regression analyses indicated that psychopathology and serotonergic alterations were best predicted by the number of ecstasy tablets taken on a typical event.ConclusionThe results indicate that verbal memory impairments were possibly aggravated after prolonged ecstasy abstinence while there was tentative evidence of serotonergic recovery. On the other hand, self-reported elevated psychopathology appeared to be associated with polydrug use in general and not specifically with ecstasy use.

[1]  J. Fisher,et al.  Neuropsychological Assessment, 2nd Ed , 1985 .

[2]  W. van den Brink,et al.  Memory disturbances in ”Ecstasy” users are correlated with an altered brain serotonin neurotransmission , 2000, Psychopharmacology.

[3]  R. Dannals,et al.  Synthesis of a radiotracer for studying serotonin uptake sites with positron emission tomography : [11C]McN-5652-Z , 1992 .

[4]  D Lehmann,et al.  Mood state and brain electric activity in Ecstasy users , 2000, Neuroreport.

[5]  H. Wechsler,et al.  Increasing MDMA use among college students: results of a national survey. , 2002, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[6]  R. Buchert,et al.  Ecstasy – long-term effects on the human central nervous system revealed by positron emission tomography , 1999, British Journal of Psychiatry.

[7]  Karl J. Friston,et al.  Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. , 1998, European journal of nuclear medicine.

[8]  R. Thomasius,et al.  Ecstasy - Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs , 2001 .

[9]  J. Langston,et al.  Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations a , 1990, Annals of the New York Academy of Sciences.

[10]  S. Kish,et al.  Brief Communications Expedited Publication Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user , 2000 .

[11]  P. Newacheck,et al.  Trends in activity-limiting chronic conditions among children. , 1986, American journal of public health.

[12]  Y Yonekura,et al.  An introduction to PET and SPECT neuroreceptor quantification models. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  S Grootoonk,et al.  Performance Evaluation of the Positron Scanner ECAT EXACT , 1992, Journal of computer assisted tomography.

[14]  A. Parrott,et al.  Auditory verbal learning in drug‐free Ecstasy polydrug users , 2001, Human psychopharmacology.

[15]  J. Fisk,et al.  Working memory deficits in current and previous users of MDMA ('ecstasy'). , 2000, British journal of psychology.

[16]  Liesbeth Reneman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[17]  Elmar Brähler,et al.  Die Symptom-Checkliste von Derogatis (SCL-90-R). , 2002 .

[18]  U. Gschwandtner,et al.  Testbatterie zur Aufmerksamkeitsprüfung (TAP) Version 1.7 , 2003 .

[19]  S. Kish.  How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.

[20]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[21]  Rodney J. Croft,et al.  The relative contributions of ecstasy and cannabis to cognitive impairment , 2001, Psychopharmacology.

[22]  R. Buchert,et al.  Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET , 2001, Nuclear medicine communications.

[23]  A. Lees,et al.  Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits , 1998, Journal of psychopharmacology.

[24]  A. Parrott,et al.  Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. , 2000, Drug and alcohol dependence.

[25]  Simon M. Ametamey,et al.  Evaluation of Serotonergic Transporters using PET and [11C](+)McN-5652: Assessment of Methods , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  P. A. Gordon.  THROWING THE BABY OUT WITH THE BATH WATER , 1995 .

[27]  U. McCann,et al.  Memory impairment in abstinent MDMA ("Ecstasy") users , 1998, Neurology.

[28]  P. Kelly.  Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.

[29]  John L. Musachio,et al.  Positron emission tomography of 5-HT reuptake sites in the human brain with C-11 McN5652 extraction of characteristic images by artificial neural network analysis , 1995, Behavioural Brain Research.

[30]  J. V. van Gerven,et al.  Cognitive performance and serotonergic function in users of ecstasy , 2000, Psychopharmacology.

[31]  Zsolt Szabo,et al.  Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.

[32]  P. McGuire,et al.  Toxic effect of MDMA on brain serotonin neurons , 1999, The Lancet.

[33]  M. Morgan.  Memory deficits associated with recreational use of “ecstasy” (MDMA) , 1999, Psychopharmacology.

[34]  H. Kung,et al.  Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  J. Fisk,et al.  Verbal working memory deficits in current and previous users of MDMA , 2004, Human psychopharmacology.

[36]  B. Schmand,et al.  Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report , 2001, Biological Psychiatry.

[37]  R. Reitan.  Trail Making Test: Manual for Administration and Scoring , 1992 .

[38]  Udo Rauchfleisch,et al.  5.4 Hamburg-Wechsler Intelligenztest für Erwachsene, Revision 1991 (Tewes, 1994) , 2001 .

[39]  H N Wagner,et al.  [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. , 1993, Life sciences.

[40]  J. Robinson,et al.  Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.

[41]  G. D. den Heeten,et al.  Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: preliminary results. , 2002, AJNR. American journal of neuroradiology.

[42]  J. Rodgers,et al.  Cognitive performance amongst recreational users of "ecstasy , 2000, Psychopharmacology.

[43]  P. Schuster,et al.  Is the Use of Ecstasy and Hallucinogens Increasing? , 1998, European Addiction Research.

[44]  G. Ricaurte,et al.  Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery , 1999, The Journal of Neuroscience.

[45]  John Hilton,et al.  Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[46]  V J Cunningham,et al.  11C-Diprenorphine Binding in Huntington's Disease: A Comparison of Region of Interest Analysis with Statistical Parametric Mapping , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  H. Sumnall,et al.  Sorted: Ecstasy facts and fiction. , 2002 .

[48]  Peter La Cour,et al.  Rivermead Behavioural Memory Test , 1990 .

[49]  G. Gerra,et al.  Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (Ecstasy) on serotonin system function in humans , 2000, Biological Psychiatry.

[50]  Klaus P. Ebmeier,et al.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.

[51]  K. Zakzanis,et al.  Executive function in abstinent MDMA ('ecstasy') users. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[52]  T. Baldeweg,et al.  Toxic effect of MDMA on brain serotonin neurons , 1999, The Lancet.

[53]  U. McCann,et al.  Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.

[54]  J. Powell,et al.  Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or ‘ecstasy’: evidence for cognitive impairment , 2001, Psychological Medicine.

[55]  G. Gerra,et al.  Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.

[56]  P. Tossmann,et al.  The Use of Drugs within the Techno Party Scene in European Metropolitan Cities , 2001, European Addiction Research.

[57]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.

[58]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[59]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  Jörg Daumann,et al.  High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users , 2000, Neuropsychopharmacology.

[61]  A. Parrott.  Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research , 2001, Human psychopharmacology.

[62]  E Y Deykin,et al.  Adolescent depression, alcohol and drug abuse. , 1987, American journal of public health.

[63]  P. McGuire,et al.  Diversity of Psychopathology Associated with use of 3,4-Methylenedioxymethamphetamine (‘Ecstasy’) , 1994, British Journal of Psychiatry.

[64]  W. van den Brink,et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.

[65]  E. Khantzian.  The Self‐Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications , 1997, Harvard review of psychiatry.

[66]  Z. Szabo,et al.  In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.

[67]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.

[68]  Y. Shaham,et al.  Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans , 1994, Neuropsychopharmacology.